ACE2 and Anosmia: Pre-vaccinated participant samples from symptom absent participants displayed significantly greater ACE2 IC50 compared to participants that presented anosmia and ageusia, cough, and fever (Table 4, S4 Fig), in line with lower antibody titers observed in the symptom absent participants.